FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Noble

Research Profile

Concepts & Ideas

Procedures

X Ray Crystallography

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Alison J Hole; Shiliang Huang; Sonja Baumli; Jane A Endicott; Peter M Fischer; Chris Pepper; Hao Shao; Shenhua Shi; Shudong Wang; Martin E M Noble
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Jonas Boehringer; Colin Gordon; Eachan O D Johnson; Christina Khoudian; Edward D Lowe; Martin E M Noble; Konstantinos Paraskevopoulos; Christiane Riedinger; Dominique Smith; Jane A Endicott
Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation.
Sonja Baumli; Alison J Hole; Martin E M Noble; Lan-Zhen Wang; Jane A Endicott
The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Noble (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alison J Hole; Shiliang Huang; Sonja Baumli; Jane A Endicott; Peter M Fischer; Chris Pepper; Hao Shao; Shenhua Shi; Shudong Wang; Martin E M Noble
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Journal of medicinal chemistry 2013;56(3):660-70.
2012: Jonas Boehringer; Colin Gordon; Eachan O D Johnson; Christina Khoudian; Edward D Lowe; Martin E M Noble; Konstantinos Paraskevopoulos; Christiane Riedinger; Dominique Smith; Jane A Endicott
Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation.
The Biochemical journal 2012;448(1):55-65.
2012: Sonja Baumli; Alison J Hole; Martin E M Noble; Lan-Zhen Wang; Jane A Endicott
The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.
Structure (London, England : 1993) 2012;20(10):1788-95.
2012: Sonja Baumli; Alison J Hole; Martin E M Noble; Jane A Endicott
The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
ACS chemical biology 2012;7(5):811-6.
2012: Jane A Endicott; Martin E M Noble; Louise N Johnson
The structural basis for control of eukaryotic protein kinases.
Annual review of biochemistry 2012;81():587-613.
2011: Anna F Watson; Qing Xu; Yan Zhao; Karim Bennaceur; Catherine J Drummond; Jane A Endicott; Bernard T Golding; Roger J Griffin; Karen Haggerty; Junfeng Liu; Xiaohong Lu; John Lunec; James M McDonnell; David R Newell; Martin E M Noble; Charlotte H Revill; Christiane Riedinger; Ian R Hardcastle
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
Bioorganic & medicinal chemistry letters 2011;21(19):5916-9.
2011: John C Sinclair; Catherine Vénien-Bryan; Karen M Davies; Martin E M Noble
Generation of protein lattices by fusing proteins with matching rotational symmetry.
Nature nanotechnology 2011;6(9):558-62.
2011: Christiane Riedinger; Martin E M Noble; David J Wright; Florian Mulks; Ian R Hardcastle; Jane A Endicott; James M McDonnell
Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy.
Chemical biology & drug design 2011;77(5):301-8.
2011: Ian R Hardcastle; Junfeng Liu; Eric Valeur; Anna Watson; Shafiq U Ahmed; Timothy J Blackburn; Karim Bennaceur; William Clegg; Catherine Drummond; Jane A Endicott; Bernard T Golding; Roger J Griffin; Jan Gruber; Karen Haggerty; Ross W Harrington; Claire Hutton; Stuart Kemp; Xiaohong Lu; James M McDonnell; David R Newell; Martin E M Noble; Sara L Payne; Charlotte H Revill; Christiane Riedinger; Qing Xu; John Lunec
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Journal of medicinal chemistry 2011;54(5):1233-43.
2010: Christiane Riedinger; Jonas Boehringer; Jean-Francois Trempe; Edward D Lowe; Nick R Brown; Kalle Gehring; Martin E M Noble; Colin Gordon; Jane A Endicott
Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12.
The Journal of biological chemistry 2010;285(44):33992-4003.
2010: Jean-Francois Trempe; Nicholas R Brown; Martin E M Noble; Jane A Endicott
A new crystal form of Lys48-linked diubiquitin.
Acta crystallographica. Section F, Structural biology and crystallization communications 2010;66(Pt 9):994-8.
2010: Suneale Banerji; Branwen R S Hide; John R James; Martin E M Noble; David G Jackson
Distinctive properties of the hyaluronan-binding domain in the lymphatic endothelial receptor Lyve-1 and their implications for receptor function.
The Journal of biological chemistry 2010;285(14):10724-35.
2010: Aude Echalier; Jane A Endicott; Martin E M Noble
Recent developments in cyclin-dependent kinase biochemical and structural studies.
Biochimica et biophysica acta 2010;1804(3):511-9.
2008: Christiane Riedinger; Jane A Endicott; Stuart J Kemp; Lynette A Smyth; Anna Watson; Eric Valeur; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Martin E M Noble; James M McDonnell
Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.
Journal of the American Chemical Society 2008;130(47):16038-44.
2008: Sonja Lorenz; Ioannis Vakonakis; Edward D Lowe; Iain D Campbell; Martin E M Noble; Maria K Hoellerer
Structural analysis of the interactions between paxillin LD motifs and alpha-parvin.
Structure (London, England : 1993) 2008;16(10):1521-31.
2008: Elizabeth Fullam; Isaac M Westwood; Matthew C Anderton; Edward D Lowe; Edith Sim; Martin E M Noble
Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase.
Journal of molecular biology 2008;375(1):178-91.
2008: Nathan Lack; Edward D Lowe; Jie Liu; Lindsay D Eltis; Martin E M Noble; Edith Sim; Isaac M Westwood
Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis.
Acta crystallographica. Section F, Structural biology and crystallization communications 2008;64(Pt 1):2-7.
2007: Victoria A Higman; Charles D Blundell; David J Mahoney; Christina Redfield; Martin E M Noble; Anthony J Day
Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography.
Journal of molecular biology 2007;371(3):669-84.
2007: Francesco Marchetti; Kerry L Sayle; Johanne Bentley; William Clegg; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Roger J Griffin; Karen Haggerty; Ross W Harrington; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Ian R Hardcastle
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.
Organic & biomolecular chemistry 2007;5(10):1577-85.
2007: Julie P I Welburn; Julie A Tucker; Tim Johnson; Lisa Lindert; Marc Morgan; Antony Willis; Martin E M Noble; Jane A Endicott
How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A.
The Journal of biological chemistry 2007;282(5):3173-81.
2007: Jan Gruber; Alexander Zawaira; Rhodri JK Saunders; C Paul Barrett; Martin E M Noble
Computational analyses of the surface properties of protein-protein interfaces.
Acta crystallographica. Section D, Biological crystallography 2007;63(Pt 1):50-7.
2006: David J Pratt; Johanne Bentley; Philip Jewsbury; F Thomas Boyle; Jane A Endicott; Martin E M Noble
Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Journal of medicinal chemistry 2006;49(18):5470-7.
2006: Robert Cheng; Martin E M Noble; Vicky Skamnaki; Nick R Brown; Edward D Lowe; Luke Kontogiannis; Kui Shen; Philip A Cole; Giuliano Siligardi; Louise N Johnson
The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition.
The Journal of biological chemistry 2006;281(32):23167-79.
2006: Roger J Griffin; Andrew Henderson; Nicola J Curtin; Aude Echalier; Jane A Endicott; Ian R Hardcastle; David R Newell; Martin E M Noble; Lan Z Wang; Bernard T Golding
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Journal of the American Chemical Society 2006;128(18):6012-3.
2006: Edward D Lowe; Na'il Hasan; Jean-Francois Trempe; Laura Fonso; Martin E M Noble; Jane A Endicott; Louise N Johnson; Nick R Brown
Structures of the Dsk2 UBL and UBA domains and their complex.
Acta crystallographica. Section D, Biological crystallography 2006;62(Pt 2):177-88.
2005: Neil Macdonald; Julie P I Welburn; Martin E M Noble; Anhco Nguyen; Michael B Yaffe; David Clynes; Jonathan G Moggs; George Orphanides; Stuart Thomson; John W Edmunds; Alison L Clayton; Jane A Endicott; Louis C Mahadevan
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3.
Molecular cell 2005;20(2):199-211.
2005: Jean-Francois Trempe; Nick R Brown; Edward D Lowe; Colin Gordon; Iain D Campbell; Martin E M Noble; Jane A Endicott
Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain.
The EMBO journal 2005;24(18):3178-89.
2005: Sandy James; Adeel Mushtaq; Simon J Holton; Pamela Schartau; Martin E M Noble; Edith Sim
Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.
The Biochemical journal 2005;390(Pt 1):115-23.
2005: C Paul Barrett; Martin E M Noble
Dynamite extended: two new services to simplify protein dynamic analysis.
Bioinformatics (Oxford, England) 2005;21(14):3174-5.
2005: C Paul Barrett; Martin E M Noble
Molecular motions of human cyclin-dependent kinase 2.
The Journal of biological chemistry 2005;280(14):13993-4005.
2005: Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.
The Biochemical journal 2005;385(Pt 2):605-12.
2005: Simon J Holton; Julien Dairou; Sandy James; Fernando Rodrigues-Lima; Jean-Marie Dupret; Martin E M Noble; Edith Sim
Structure of Mesorhizobium loti arylamine N-acetyltransferase 1.
Acta crystallographica. Section F, Structural biology and crystallization communications 2005;61(Pt 1):14-6.
2004: C Paul Barrett; Benjamin Andrew Hall; Martin E M Noble
Dynamite: a simple way to gain insight into protein motions.
Acta crystallographica. Section D, Biological crystallography 2004;60(Pt 12 Pt 1):2280-7.
2004: Ian R Hardcastle; Christine E Arris; Johanne Bentley; F Thomas Boyle; Yuzhu Chen; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Jerome Menyerol; Veronique Mesguiche; David R Newell; Martin E M Noble; David J Pratt; Lan Z Wang; Hayley J Whitfield
N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
Journal of medicinal chemistry 2004;47(15):3710-22.
2004: David J Pratt; Jane A Endicott; Martin E M Noble
The role of structure in kinase-targeted inhibitor design.
Current opinion in drug discovery & development 2004;7(4):428-36.
2004: Martin E M Noble; Jane A Endicott; Louise N Johnson
Protein kinase inhibitors: insights into drug design from structure.
Science (New York, N.Y.) 2004;303(5665):1800-5.
2003: Maria K Hoellerer; Martin E M Noble; Gilles Labesse; Iain D Campbell; Joern Werner; Stefan T Arold
Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain.
Structure (London, England : 1993) 2003;11(10):1207-17.
2003: Kerry L Sayle; Johanne Bentley; F Thomas Boyle; A Hilary Calvert; Yuzhu Cheng; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Ian R Hardcastle; Philip Jewsbury; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Roger J Griffin
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(18):3079-82.
2003: Veronique Mesguiche; Rachel J Parsons; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Louise N Johnson; David R Newell; Martin E M Noble; Lan Z Wang; Ian R Hardcastle
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(2):217-22.
2002: Edward D Lowe; Ivo Tews; Robert Cheng; Nick R Brown; Sheraz Gul; Martin E M Noble; Steven J Gamblin; Louise N Johnson
Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.
Biochemistry 2002;41(52):15625-34.
2002: Thomas G Davies; Johanne Bentley; Christine E Arris; F Thomas Boyle; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Lan Wang; Hayley J Whitfield
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Nature structural biology 2002;9(10):745-9.
2002: Ashleigh E Gibson; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Bernard T Golding; Sharon Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Hayley J Whitfield
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Journal of medicinal chemistry 2002;45(16):3381-93.
2002: Stefan T Arold; Maria K Hoellerer; Martin E M Noble
The structural basis of localization and signaling by the focal adhesion targeting domain.
Structure (London, England : 1993) 2002;10(3):319-27.
2002: Thomas G Davies; David J Pratt; Jane A Endicott; Louise N Johnson; Martin E M Noble
Structure-based design of cyclin-dependent kinase inhibitors.
Pharmacology & therapeutics 2002;93(2-3):125-33.
2002: Louise N Johnson; Erika De Moliner; Nick R Brown; Haiwei Song; David Barford; Jane A Endicott; Martin E M Noble
Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
Pharmacology & therapeutics 2002;93(2-3):113-24.
2001: AM Lawrie; Paula Tito; H Hernandez; Nick R Brown; Carol V Robinson; Jane A Endicott; Martin E M Noble; Louise N Johnson
Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells.
Protein expression and purification 2001;23(2):252-60.
2001: Stefan T Arold; Tobias S Ulmer; TD Mulhern; Joern Werner; John E Ladbury; Iain D Campbell; Martin E M Noble
The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases.
The Journal of biological chemistry 2001;276(20):17199-205.
2001: Thomas G Davies; P Tunnah; Laurent Meijer; Doris Marko; Gerhard Eisenbrand; Jane A Endicott; Martin E M Noble
Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Structure (London, England : 1993) 2001;9(5):389-97.
2001: H Song; N Hanlon; Nick R Brown; Martin E M Noble; Louise N Johnson; David Barford
Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2.
Molecular cell 2001;7(3):615-26.
2000: Christine E Arris; F Thomas Boyle; A Hilary Calvert; Nicola J Curtin; Jane A Endicott; E F Garman; Ashleigh E Gibson; Bernard T Golding; S Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; AM Lawrie; David R Newell; Martin E M Noble; Edward A Sausville; R Schultz; W Yu
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Journal of medicinal chemistry 2000;43(15):2797-804.
2000: J C Sinclair; Sandy James; Rupika Delgoda; Edith Sim; Martin E M Noble
Structure of arylamine N-acetyltransferase reveals a catalytic triad.
Nature structural biology 2000;7(7):560-4.
1999: Jane A Endicott; Martin E M Noble; Julie A Tucker
Cyclin-dependent kinases: inhibition and substrate recognition.
Current opinion in structural biology 1999;9(6):738-44.
1999: Vicky Skamnaki; David J Owen; Martin E M Noble; Edward D Lowe; G Lowe; Nikos G Oikonomakos; Louise N Johnson
Catalytic mechanism of phosphorylase kinase probed by mutational studies.
Biochemistry 1999;38(44):14718-30.
1999: Nick R Brown; Martin E M Noble; Jane A Endicott; Louise N Johnson
The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Nature cell biology 1999;1(7):438-43.
1999: David J Owen; Yvonne Vallis; Martin E M Noble; J B Hunter; T R Dafforn; Philip R Evans; Harvey T McMahon
A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain.
Cell 1999;97(6):805-15.
1999: Martin E M Noble; Jane A Endicott
Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
Pharmacology & therapeutics 1999;82(2-3):269-78.
1999: Nick R Brown; Martin E M Noble; AM Lawrie; M C Morris; P Tunnah; G Divita; Louise N Johnson; Jane A Endicott
Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.
The Journal of biological chemistry 1999;274(13):8746-56.
1998: Louise N Johnson; Edward D Lowe; Martin E M Noble; David J Owen
The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases.
FEBS letters 1998;430(1-2):1-11.
1998: Jane A Endicott; Martin E M Noble
Structural principles in cell-cycle control: beyond the CDKs.
Structure (London, England : 1993) 1998;6(5):535-41.
1998: M Gregoriou; Martin E M Noble; Kimberly A Watson; E F Garman; T M Krulle; C de la Fuente; George W J Fleet; Nikos G Oikonomakos; Louise N Johnson
The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding.
Protein science : a publication of the Protein Society 1998;7(4):915-27.
1998: J C Sinclair; Rupika Delgoda; Martin E M Noble; S Jarmin; N K Goh; Edith Sim
Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium.
Protein expression and purification 1998;12(3):371-80.
1997: Martin E M Noble; Jane A Endicott; Nick R Brown; Louise N Johnson
The cyclin box fold: protein recognition in cell-cycle and transcription control.
Trends in biochemical sciences 1997;22(12):482-7.
1997: Edward D Lowe; Martin E M Noble; Vicky Skamnaki; Nikos G Oikonomakos; David J Owen; Louise N Johnson
The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition.
The EMBO journal 1997;16(22):6646-58.
1997: AM Lawrie; Martin E M Noble; P Tunnah; Nick R Brown; Louise N Johnson; Jane A Endicott
Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
Nature structural biology 1997;4(10):796-801.
1997: Louise N Johnson; David Barford; David J Owen; Martin E M Noble; E F Garman
From phosphorylase to phosphorylase kinase.
Advances in second messenger and phosphoprotein research 1997;31():11-28.
1996: Louise N Johnson; Martin E M Noble; David J Owen
Active and inactive protein kinases: structural basis for regulation.
Cell 1996;85(2):149-58.
1995: Nick R Brown; Martin E M Noble; Jane A Endicott; Elspeth F Garman; S Wakatsuki; E Mitchell; B Rasmussen; Tim Hunt; Louise N Johnson
The crystal structure of cyclin A.
Structure (London, England : 1993) 1995;3(11):1235-47.
1995: John Francis Timms; Martin E M Noble; M Gregoriou
An investigation of the role of Glu-842, Glu-844 and His-846 in the function of the cytoplasmic domain of the epidermal growth factor receptor.
The Biochemical journal 1995;308 ( Pt 1)():219-29.
1995: David J Owen; Martin E M Noble; Elspeth F Garman; Anastassios C Papageorgiou; Louise N Johnson
Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product.
Structure (London, England : 1993) 1995;3(5):467-82.
1995: Jane A Endicott; Martin E M Noble; Elspeth F Garman; N Brown; B Rasmussen; Paul Nurse; Louise N Johnson
The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein.
The EMBO journal 1995;14(5):1004-14.
1995: David J Owen; Anastassios C Papageorgiou; Elspeth F Garman; Martin E M Noble; Louise N Johnson
Expression, purification and crystallisation of phosphorylase kinase catalytic domain.
Journal of molecular biology 1995;246(3):374-81.
1994: Martin E M Noble; Anne Cleasby; Louise N Johnson; Maarten R Egmond; Leon G J Frenken
Analysis of the structure of Pseudomonas glumae lipase.
Protein engineering 1994;7(4):559-62.
1993: Martin E M Noble; Anne Cleasby; Louise N Johnson; M R Egmond; Leon G J Frenken
The crystal structure of triacylglycerol lipase from Pseudomonas glumae reveals a partially redundant catalytic aspartate.
FEBS letters 1993;331(1-2):123-8.